279 related articles for article (PubMed ID: 8888661)
21. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries.
Johansson I; Joseph P; Balasubramanian K; McMurray JJV; Lund LH; Ezekowitz JA; Kamath D; Alhabib K; Bayes-Genis A; Budaj A; Dans ALL; Dzudie A; Probstfield JL; Fox KAA; Karaye KM; Makubi A; Fukakusa B; Teo K; Temizhan A; Wittlinger T; Maggioni AP; Lanas F; Lopez-Jaramillo P; Silva-Cardoso J; Sliwa K; Dokainish H; Grinvalds A; McCready T; Yusuf S;
Circulation; 2021 Jun; 143(22):2129-2142. PubMed ID: 33906372
[TBL] [Abstract][Full Text] [Related]
22. Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
Lam PH; Dooley DJ; Fonarow GC; Butler J; Bhatt DL; Filippatos GS; Deedwania P; Forman DE; White M; Fletcher RD; Arundel C; Blackman MR; Adamopoulos C; Kanonidis IE; Aban IB; Patel K; Aronow WS; Allman RM; Anker SD; Pitt B; Ahmed A
Eur J Heart Fail; 2018 Feb; 20(2):359-369. PubMed ID: 28980368
[TBL] [Abstract][Full Text] [Related]
23. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Tsuyuki RT; Yusuf S; Rouleau JL; Maggioni AP; McKelvie RS; Wiecek EM; Wang Y; Pogue J; Teo KK; White M; Avezum A; Latini R; Held P; Lindgren E; Probstfield J
Can J Cardiol; 1997 Dec; 13(12):1166-74. PubMed ID: 9444298
[TBL] [Abstract][Full Text] [Related]
24. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
[TBL] [Abstract][Full Text] [Related]
25. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
; Yusuf S; Pitt B; Davis CE; Hood WB; Cohn JN
N Engl J Med; 1992 Sep; 327(10):685-91. PubMed ID: 1463530
[TBL] [Abstract][Full Text] [Related]
26. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
Konstam MA; Kronenberg MW; Rousseau MF; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D
Circulation; 1993 Nov; 88(5 Pt 1):2277-83. PubMed ID: 8222122
[TBL] [Abstract][Full Text] [Related]
27. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
Yusuf S
Herz; 1993 Dec; 18 Suppl 1():444-8. PubMed ID: 8125425
[TBL] [Abstract][Full Text] [Related]
28. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
Vermes E; Ducharme A; Bourassa MG; Lessard M; White M; Tardif JC;
Circulation; 2003 Mar; 107(9):1291-6. PubMed ID: 12628950
[TBL] [Abstract][Full Text] [Related]
29. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction.
Suskin N; Sheth T; Negassa A; Yusuf S
J Am Coll Cardiol; 2001 May; 37(6):1677-82. PubMed ID: 11345383
[TBL] [Abstract][Full Text] [Related]
30. Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril.
Sturm B; Pacher R; Strametz-Juranek J; Berger R; Frey B; Stanek B
Eur J Heart Fail; 2000 Dec; 2(4):407-12. PubMed ID: 11113718
[TBL] [Abstract][Full Text] [Related]
31. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.
Glick H; Cook J; Kinosian B; Pitt B; Bourassa MG; Pouleur H; Gerth W
J Card Fail; 1995 Dec; 1(5):371-80. PubMed ID: 12836712
[TBL] [Abstract][Full Text] [Related]
32. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
[TBL] [Abstract][Full Text] [Related]
33. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
[TBL] [Abstract][Full Text] [Related]
34. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
Anker SD; Negassa A; Coats AJ; Afzal R; Poole-Wilson PA; Cohn JN; Yusuf S
Lancet; 2003 Mar; 361(9363):1077-83. PubMed ID: 12672310
[TBL] [Abstract][Full Text] [Related]
35. Racial differences in the outcome of left ventricular dysfunction.
Dries DL; Exner DV; Gersh BJ; Cooper HA; Carson PE; Domanski MJ
N Engl J Med; 1999 Feb; 340(8):609-16. PubMed ID: 10029645
[TBL] [Abstract][Full Text] [Related]
36. The effect of gender on outcome in digitalis-treated heart failure patients.
Domanski M; Fleg J; Bristow M; Knox S
J Card Fail; 2005 Mar; 11(2):83-6. PubMed ID: 15732025
[TBL] [Abstract][Full Text] [Related]
37. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.
Exner DV; Dries DL; Waclawiw MA; Shelton B; Domanski MJ
J Am Coll Cardiol; 1999 Mar; 33(4):916-23. PubMed ID: 10091816
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
[TBL] [Abstract][Full Text] [Related]
39. Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
Gregory DD; Sarnak MJ; Konstam MA; Pereira B; Salem D
Am J Cardiol; 2003 Dec; 92(11):1300-5. PubMed ID: 14636907
[TBL] [Abstract][Full Text] [Related]
40. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.
Shindler DM; Kostis JB; Yusuf S; Quinones MA; Pitt B; Stewart D; Pinkett T; Ghali JK; Wilson AC
Am J Cardiol; 1996 May; 77(11):1017-20. PubMed ID: 8644628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
